Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 7/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21089 | 0.81 | MIF (0.44) | MIFTRPA1ALDH1A1HPGDCYP3A4 | |
| SCHEMBL5500494 | 0.81 | ALDH1A1 (0.47) | ALDH1A1HPGDHSD17B10CYP3A4 | |
| SCHEMBL2983108 | 0.79 | NAAA (0.47) | MIFTRPA1ALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL13479749 | 0.79 | ALDH1A1 (0.49) | ALDH1A1HSD17B10CYP3A4TSHR | |
| SCHEMBL22471901 | 0.79 | MIF (0.43) | MIFTRPA1ALDH1A1HPGDCYP3A4 | |
| Water SCHEMBL29040332 | 0.79 | MIF (0.43) | MIFTRPA1ALDH1A1HPGDCYP3A4 | |
| Water SCHEMBL14972874 | 0.79 | MIF (0.43) | MIFTRPA1ALDH1A1HPGDCYP3A4 | |
| SCHEMBL18567327 | 0.78 | MIF (0.42) | MIFTRPA1ALDH1A1HPGDCYP3A4 | |
| SCHEMBL14328197 | 0.76 | MIF (0.35) | MIFTRPA1ALDH1A1HPGDCYP3A4 | |
| SCHEMBL28911026 | 0.76 | MIF (0.39) | MIFTRPA1ALDH1A1HPGDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028536-A1 | INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | KANONCURE, INC. (JP) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028536-A1 | INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | MMP1, SERPINB1, LGALS1 | MIF 17/4885TRPA1 2948/4885ALDH1A1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.